Precision medicine in clinical oncology: the journey from IgG antibody to IgE.

Abstract

PURPOSE OF REVIEW:

Cancer is one of the leading causes of death and the incidence rates are constantly rising. The heterogeneity of tumors poses a big challenge for the treatment of the disease and natural antibodies additionally affect disease progression. The introduction of engineered mAbs for anticancer immunotherapies has substantially improved progression-free and overall survival of cancer patients, but little efforts have been made to exploit other antibody isotypes than IgG.

RECENT FINDINGS:

In order to improve these therapies, 'next-generation antibodies' were engineered to enhance a specific feature of classical antibodies and form a group of highly effective and precise therapy compounds. Advanced antibody approaches include among others antibody-drug conjugates, glyco-engineered and Fc-engineered antibodies, antibody fragments, radioimmunotherapy compounds, bispecific antibodies and alternative (non-IgG) immunoglobulin classes, especially IgE.

SUMMARY:

The current review describes solutions for the needs of next-generation antibody therapies through different approaches. Careful selection of the best-suited engineering methodology is a key factor in developing personalized, more specific and more efficient mAbs against cancer to improve the outcomes of cancer patients. We highlight here the large evidence of IgE exploiting a highly cytotoxic effector arm as potential next-generation anticancer immunotherapy.

• Authors: Judit Fazekas-Singer, Josef Singer, Erika Jensen-Jarolim
• Journal: Current opinion in allergy and clinical immunology (Curr Opin Allergy Clin Immunol) Vol. 20 Issue 3 Pg. 282-289 (06 2020) ISSN: 1473-6322 [Electronic] United States
• PMID: 32349107 (Publication Type: Journal Article)

Chemical References

• Antibodies, Bispecific
• Antibodies, Monoclonal
• Antineoplastic Agents, Immunological
• Immunoconjugates
• Immunoglobulin Fc Fragments
• Immunoglobulin E

Topics

• Antibodies, Bispecific (therapeutic use)
• Antibodies, Monoclonal (therapeutic use)
• Antineoplastic Agents, Immunological (therapeutic use)
• Drug Resistance, Neoplasm (genetics)
• Humans
• Immunoconjugates (therapeutic use)
• Immunoglobulin E (therapeutic use)
• Immunoglobulin Fc Fragments (therapeutic use)
• Medical Oncology (methods, trends)
• Neoplasms (drug therapy, genetics, immunology, mortality)
• Precision Medicine (methods, trends)
• Progression-Free Survival
• Protein Engineering
• Radioimmunotherapy (methods, trends)
• Tumor Escape (genetics)